Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
JAMA Network Open|September 16, 2022
Effectiveness of Single vs Multiple Doses of Prophylactic Intravenous Antibiotics in Implant-Based Breast Reconstruction: A Randomized Clinical TrialJessica Gahm, Anna Ljung Konstantinidou, Jakob Lagergren, et al.
Anticancer Research|May 6, 2021
Pretreatment MRI in Primary Rectal Cancer as a Predictor for Oncological Outcomes After Surgery for Local RecurrenceAnders H Elliot, Barwar N Othman, Chikako Suzuki, et al.
Plos One|June 16, 2012
Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancerAnders Näsman, Mircea Romanitan, Cecilia Nordfors, et al.
BMC Cancer|May 28, 2017
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trialJana de Boniface, Jan Frisell, Yvette Andersson, et al.
British Journal of Anaesthesia|November 21, 2024
Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trialEmma Hasselgren, Nina Groes-Kofoed, Henrik Falconer, et al.
British Journal of Haematology|August 12, 2020
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patientsAgnes Mattsson, Sandra E Sylvan, Anna Asklid, et al.
Acta Anaesthesiologica Scandinavica|August 26, 2025
Prospective Assessment of Clinically Relevant Fluid Balance Thresholds Associated With Postoperative Complications in Advanced Ovarian CancerEmma Hasselgren, Nina Groes Kofoed, Henrik Falconer, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
The Lancet. Oncology|February 14, 2017
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trialJohan Erlandsson, Torbjörn Holm, David Pettersson, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
Pageof 11